UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 31, 2017
Leap Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-37990 | | 27-4412575 |
(State or other jurisdiction | | (Commission | | (IRS Employer |
of incorporation) | | File Number) | | Identification No.) |
47 Thorndike Street, Suite B1-1
Cambridge, MA | | 02141 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (617) 714-0360
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Introductory Comment
Throughout this Current Report on Form 8-K, the terms “Leap”, “we,” “us,” “our” and “Company” refer to Leap Therapeutics, Inc.
Item 2.02. Results of Operations and Financial Condition.
On March 31, 2017, Leap Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2016 and progression-free survival data in advanced biliary tract cancer. The full text of the press release is attached Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | | Description |
99.1 | | Press release dated March 31, 2017 issued by Leap Therapeutics, Inc. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
Date: March 31, 2017 | | LEAP THERAPEUTICS, INC. |
| | (Registrant) |
| | |
| | By: | /s/ Christopher Mirabelli, Ph.D. |
| | Name: | Christopher Mirabelli, Ph.D. |
| | Title: | Chief Executive Officer |
3
EXHIBIT INDEX
Exhibit No. | | Description |
99.1 | | Press release dated March 31, 2017 issued by Leap Therapeutics, Inc. |
4
